Patient-derived tumor models of esophageal cancer

Tomoki Saito; Shinya Ohashi; Ayaka Mizumoto; Manabu Muto

doi:10.1016/bs.enz.2019.10.003

Patient-derived tumor models of esophageal cancer

Enzymes. 2019:46:97-111. doi: 10.1016/bs.enz.2019.10.003. Epub 2019 Nov 6.

Authors

Tomoki Saito¹, Shinya Ohashi¹, Ayaka Mizumoto², Manabu Muto³

Affiliations

¹ Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; KBBM Inc., Kyoto, Japan.
³ Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: mmuto@kuhp.kyoto-u.ac.jp.

PMID: 31727279
DOI: 10.1016/bs.enz.2019.10.003

Abstract

Tumor models are powerful tools to plan preclinical therapeutic strategies that cannot be conducted on humans. Recently, patient-derived tumor models such as patient-derived xenograft (PDX) and/or patient-derived organoid (PDO), are widely used to investigate the antitumor effects of various drugs, because those tumors resemble original tumors at the physiological and molecular level. In this chapter, we describe patient-derived tumor models of esophageal cancers and outline the latest research as well as the molecular pathology of esophageal cancers.

Keywords: Esophageal cancer; Patient-derived organoid (PDO); Patient-derived xenograft (PDX).

MeSH terms

Animals
Disease Models, Animal
Esophageal Neoplasms / pathology*
Humans
Xenograft Model Antitumor Assays